Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5508 combinations in advanced solid tumors
NCT07256782Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of MHB088C in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Started Oct 2025; status: recruiting.
02
Drugs
MHB088C
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07256782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256782.